Biotech Co.* (Symbol) | Pharma Co. (Country) | Type/Product Area | Disclosed Funding (M) | Terms/Details (Date) |
Acadia Pharmaceuticals* | Parexel International | Collaborative agreement for pharmacogenomic | ND | Parexel will assist clients developing neuropsychiatric products in using Acadia's functional genomics platform to streamline the clinical development process for central nervous system compounds (11/28) |
Admetric BioChem Inc.* | SmithKline Beecham Pharmaceuticals | Agreement for the development and evaluation of Admetric's technology to profile and prioritize compounds for drug development | ND | Admetrix will provide the ADMET properties of up to 125 SmithKline compounds; the data will then become part of the MAF database; Admetrix has granted SmithKline an option to negotiate a long-term agreement for access to Admetrix's technology and database; S.R. One Ltd. led the initial venture capital investment (11/2) |
AltaRex Corp. (Canada; TSE:AXO; OTC BB:ALRXF) | Dompe Farmaceutici SpA (Italy) | Memorandum of understanding to form an alliance for OvaRex MAb | $5 | The memorandum gives Dompe the rights of first offer for additional cancer antibodies in Italy, Spain, Portugal, Switzerland, Austria and certain Eastern European countries; Dompe has escrowed $5M to purchase AltaRex common shares through a private placement; Dompe has the option to purchase an additional $5M in equity and will pay up to $1.25M upon OvaRex MAb commercialization in Spain and Portugal (11/16) |
Arakis Ltd.* | Penwest Pharmaceuticals | Joint development agreement for AD 121 | ND | The companies will jointly develop the compound and share equally in commercialization profits (11/13) |
ArQule Inc. (ARQL) | SmithKline Beecham plc | Drug discovery collaboration to identify, optimize and deliver clinical candidates | ND | ArQule will optimize lead compounds in at least two programs, the first compound identified by SmithKline and the second identified from the Compass Array library; the agreement includes research and development payments, milestone payments and royalties (11/28) |
Atrix Laboratories Inc. (ATRX) | Geneva Pharmaceuticals Inc. (member of the Novartis AG group) | Collaboration agreement to develop and manufacture prescription generic dermatology products | ND | Alliance has targeted a number of products to develop over a 10-year period; Geneva will market the products developed by Atrix under a profit sharing agreement (10/30) |
Avant Immunotherapeutics Inc. (AVAN) | Pfizer Inc. | Development agreement for vaccines | $5.5 | Pfizer will develop animal health and food safety vaccines based on technology from Megan Health, which was acquired by Avant; Pfizer will pay $2.5M in an up-front license fee and make a $3M equity investment in Avant (12/4) |
BCY LifeSciences Inc. (Canada; VSE:BCY) | AP Biotech (formerly called Amersham Pharmacia Biotech; Sweden) | Supply agreement for DCF 987 | ND | AP Biotech will become the prime supplier for DCF 987, the active ingredient in BCY's lead product targeting cystic fibrosis and other lung disorders (10/25) |
BioNumerik Pharmaceuticals Inc.* | Grelan Pharmaceutical Co. Ltd. (Japan) | Joint venture focused on oncologics | ND | Companies formed KI Pharmaceuticals LLC to focus on oncologics and enhance the Eastern presence of BioNumerik (11/15) |
BioStratum Inc.* | Shire Laboratories Inc. (unit of Shire Pharmaceuticals Group plc) | Development agreement for Pyridorin | ND | The companies will develop an extended-release formulation of Bio-Stratum's Pyridorin for kidney disease, which BioStratum will use in upcoming Phase III trials (11/29) |
CeNeS Pharmaceuticals plc (UK; LSE:CEN) | Glaxo Wellcome plc (UK) | Purchase agreement for the high-throughput ion channel screening technology | ND | The companies will collaborate to enhance screening throughput of the system, called AutoPatch (12/13**) |
ChemBridge Corp.* | AstraZeneca plc (UK) | Agreement for non-exclusive access to PHARMA-Core library | ND | AstraZeneca will use the library, intended to streamline the process of screening-based drug discovery (10/26) |
ChemBridge Corp.* | Bristol-Myers Squibb Co. | Non-exclusive license for access to ChemBridge's PHARMACore combinatorial lead discovery library | ND | Financial terms were ND (11/3) |
Cubist Pharmaceuticals Inc. (CBST) | Novartis Pharma AG (Switzerland) | Extended collaboration | ND | Companies extended the collaboration begun in February 1999 in which Cubist recently achieved a milestone for the delivery of a novel anti-infective target and drug discovery assay; the alliance is extended for one year (11/10) |
Cytokine PharmaSciences Inc.* | Elan Corp. plc (Ireland) | Formation of a joint venture company to develop the cytokine inhibitor, CNI-1493, using Elan's NanoCrystal formulation technology | ND | The primary focus will be on Crohn's disease and other inflammatory conditions; both parties will contribute technology and other resources; Elan took an option to market CNI-1493 in noninfectious diseases upon completion of development (10/23) |
CytRx Corp. (CYTR) | Merck & Co. Inc. | License agreement for TranzFect technology in DNA-based vaccines | ND | CytRx will receive an up-front payment and potential milestone and royalty payments (11/6) |
Diversa Corp. (DVSA) | Glaxo Research and Development Ltd. (unit of Glaxo Wellcome plc; UK) | Drug discovery research collaboration to identify drugs derived from the recombinant multi-gene PathwayLibraries | ND | Companies will jointly perform research to identify small molecules from Diversa's PathwayLibraries, and to screen these molecules; Glaxo will receive exclusive worldwide rights to designated biomolecules (12/12) |
DoubleTwist Inc.* | Merck & Co. Inc. | Licensing agreement for Prophecy | ND | Agreement grants Merck rights to the Prophecy annotated human genome database and associated software for data interpretation (11/29) |
Ecopia BioSciences* (Canada) | Merck & Co. Inc. | A 12-month agreement for research in an undisclosed area | US$.125 | The agreement will cover a 12-month period and will involve scheduled payments totaling US$125,000; both parties agreed not to disclose the other terms and the field of the agreement (10/23) |
Entelos Inc.* | Bristol-Myers Squibb Co. | Collaboration to evaluate various approaches to regulate human body mass and adipose tissue mass regulation approaches | ND | Entelos will use its PhysioLab technology to provide insight into different pathophysiologies leading to obesity and approaches to treat them (12/13) |
Evolutec Ltd.* TD> |
Novartis Animal Health Inc. (Switzerland) | Joint research program for farm and companion animal vaccines | ND | Companies will determine if molecules discovered by Evolutec could be developed into farm and companion animal vaccines (11/15**) |
EyeTech Pharmaceuticals Inc.* | Iomed Inc. | Collaboration to develop a non-invasive drug delivery system for EyeTech's therapy targeting age-related macular degeneration | ND | EyeTech's therapeutic, EYE001, will be tested in Iomed's OcuPhor non-invasive transscleral delivery system for active drug transport to the retina and sub-retinal tissues of the eye (10/24) |
FeRx Inc.* | Elan Corp. plc (Ireland) | Partnership to develop, manufacture and commercialize MTC-DOX to treat primary liver cancer | ND | Financial terms include equity and milestone payments to FeRx; the companies will share the costs of development, as well as commercialization revenues (11/28) |
Genaissance Pharmaceuticals Inc. (GNSC) | Janssen Research Foundation (unit of Johnson & Johnson; NYSE:JNJ) | Multiyear, worldwide agreement for discovery, development and commercialization of HAP technology | ND | As part of the agreement, the R.W. Johnson Pharmaceutical Research Institute also will gain a license to the technology; terms were ND (11/27) |
Genome Therapeutics Corp. (GENE) | Bristol-Myers Squibb Co. | Extended licensing agreement for the PathoGenome database | ND | Bristol-Myers' researchers will continue to use the database to identify new gene targets to discover therapies for bacterial and fungal infections; Bristol-Myers will continue to have non-exclusive access to the database and will pay annual subscription fees, milestone payments and royalties (12/6) |
Genomica Corp. (GNOM) | Aventis Pharma (unit of Aventis SA; France) | Licensing agreement for the Discovery Manager software | ND | Genomica licensed its Discovery Manager software to Aventis (11/2) |
Gilead Sciences Inc. (GILD) | Glaxo Group Ltd. and Glaxo Wellcome Inc. (units of Glaxo Wellcome plc; UK) | Exclusive, worldwide development and marketing agreement for GW1843U89 to treat cancer | ND | Gilead paid Glaxo an up-front license fee and will make milestone payments, as well as royalty payments; it also will cover research and development costs (12/5) |
Hemispherx Biopharma Inc. (AMEX:HEB) | Ie Sung International (Korea and Japan) | Agreement to accelerate development of Hemispherx's clinical programs in chronic viral diseases | ND | Agreement is for selected Pacific Rim countries (12/5) |
ICN Pharmaceuticals Inc. (NYSE:ICN) | Schering-Plough Corp. | Long-term strategic agreement to license drugs to treat hepatitis C and other indications | ND | Schering-Plough has the right of first and last refusal to license two antiviral drugs, levovirin and viramidine, and other compounds that ICN may develop, as well as the exclusive option for a worldwide license for up to three hepatitis C drugs to be developed by ICN (11/15) |
Incyte Genomics Inc. (INCY) | Sumitomo Pharmaceuticals Co. Ltd. (Japan) | Licensing agreement for Incyte's databases | ND | Sumitomo will license Incyte's LifeSeq Gold database, as well as the ZooSeq animal model database (12/4) |
InSite Vision Inc. (AMEX:ISV) | SSP Co. Ltd. (Japan) | Licensing agreement for two fluoroquinolone compounds, SS732 and SS734 | ND | InSite will develop SS734 into an ophthalmic dosage form, which will use the DuraSite technology; InSite will have exclusive rights, with the exception of Japan; the two companies will share the rights in Asia (12/13) |
Karo Bio USA (unit of Karo Bio AB; Sweden; SSE:KARO) | Aventis Pharma (unit of Aventis SA; France) | Strategic alliance concerning Karo Bio's BioKey drug discovery technology | $32 | Karo Bio agreed to provide Aventis with access to the BioKey drug discovery technology for targets identified through Aventis' genomics programs; Aventis has an option to extend the initial one-year term to three additional years; the value of the agreement can exceed $32M for Karo Bio, excluding royalties and assuming the development of two compounds (10/23) |
Karo Bio AB (Sweden; SSE:KARO) | Merck & Co. Inc. | Two-year extension to drug discovery collaboration on estrogen receptors | ND | The collaboration has been successful in design and synthesis of selective compounds (10/30) |
Lexicon Genetics Inc. (LEXG) | Eli Lilly & Co. | Non-exclusive sublicense for the use of certain aspects of Lexicon's positive-negative selection and isotonic DNA technologies | ND | Lilly will use the technologies in its internal discovery and target validation programs (11/16) |
Lyotropic Therapeutics Inc.* | Elan Pharmaceutical Technologies (unit of Elan Corp. plc; Ireland) | Joint venture for the research, development and commercialization of pharmaceutical products | ND | The companies will develop the products using Lyotropic's LyoCell and Elan's NanoCrystal drug delivery technologies; the joint venture will be a subsidiary of Lyotropic (11/27) |
Medarex Inc. (MEDX) | Eli Lilly & Co. | Agreement to produce fully human antibodies for a number of Lilly disease targets | ND | Medarex will receive an immunization fee for each target against which it raises an antibody; Medarex also will receive license fees, as well as payments for milestones and potential royalties (11/6) |
Microcide Pharmaceuticals Inc. (MCDE) | Schering-Plough Animal Health | Research collaboration and license agreement to discover and develop improved veterinary antimicrobial drugs | ND | Schering-Plough will have worldwide rights to products resulting; Microcide will receive an up-front payment and research support payments over two years, and milestone and royalty payments on resulting products (11/1) |
NeoGenesis Inc.* | Merck & Co. Inc. | Collaborative research agreement | ND | NeoGenesis will uses its Chemical Genomics technology platform to identify and optimize chemical compounds for new drug discovery leads against multiple targets (12/11) |
Neurome Inc.* | Elan Corp. plc (Ireland) | Research partnership for three years | $4 | The partnership may generate up to $4M in service revenue for Neurome, along with shared ownership of the diagnostic and therapeutic applications of the genes, circuits and mechanisms identified in the research; the parties will analzye a mouse model of Alzheimer's disease to identify and exploit molecules and pathways relevant to diagnosis and treatment (10/20) |
Oncolytics Biotech Inc. (Canada; TSE:ONC) | Pfizer Inc. | Worldwide licensing agreement for reovirus | ND | Agreement is for the development and marketing of reovirus for animal use (11/20) |
Oxford GlycoSciences plc (UK; LSE:OGS) | Glaxo Wellcome plc (UK) | Multi-disease biomarker collaboration | ND | Collaboration will use high-throughput proteomics technology; Glaxo Wellcome will fund research and may obtain an exclusive right to negotiate for the acquisition of OGS's diagnostic rights (12/4) |
Packard BioScience Co. (PBSC) and BioSignal Packard Inc. (unit of Packard BioScience Co.; PBSC) | AstraZeneca R&D Montreal (Canada) | Expanded screening contract | US$5.5 | The contract follows on the heels of a three-year contract between Astra-Zeneca and BioSignal, which ended in September; BioSignal's technologies will be used to test AstraZeneca's combinatorial compound libraries against a defined selection of G protein-coupled receptors (10/23) |
PPD Discovery (unit of PPD Inc.; PPDI) | Aventis SA (France) | Expanded functional genomics alliance | ND | Aventis will fund scientists to develop new therapeutic agents in oncology, inflammation, cardiovascular disease and central nervous system disorders (11/9) |
Rosetta Inpharmatics Inc. (RSTA) | Glaxo Wellcome plc (UK) | Licensing agreement for the Rosetta Resolver Expression Data Analysis System | ND | Glaxo licensed the system from Rosetta; terms were ND (12/11) |
Southern BioSystems Inc.* | Alcon Pharmaceuticals | Agreement to develop controlled-release products for certain ophthalmic indications | ND | Alcon will have exclusive access to SBS' microencapsulation technology for development of products to treat diseases affecting the back of the eye; SBS will receive product development funding, as well as milestone and royalty payments (12/12) |
Targeted Genetics Corp. (TGEN) | American Home Products Corp. | Collaboration to develop gene therapy products to treat hemophilia | $80 | TGEN will develop the products with Genetics Institute, a division of Wyeth-Ayerst, a division of AHP; Genetics Institute will pay TGEN $5M up-front, up to $15M for development of the factor VIII product over the next three years, as well as development and commercialization milestones; Genetics Institute also has the option to collaborate on the development of AAV delivery of the gene encoding factor IX to treat hemophilia B, and has agreed to loan TGEN up to $10M to finance manufacturing facility expansions (11/9) |
Targeted Molecules Corp.* | Elan Corp. plc (Ireland)< /TD> |
Strategic partnership to develop and commercialize peptide targeting and drug delivery technologies | ND | Partnership has an initial term of three years and companies will share ownership of the intellecutal property and products developed (11/16) |
Techniclone Corp. (TCLN) | Merck KGaA (Germany) | Agreement for a segment of Techniclone's Tumor Necrosis Therapy | ND | Techniclone will grant Merck the right to use its TNT antibodies for producing immunocytokines; the agreement involves an undisclosed up-front payment and a royalty on potential sales (10/23) |
Tripos Inc. (TRPS) | Novo Nordisk AS (Denmark) | Research collaboration to design and develop new software products for pharmaceutical research | ND | Tripos will develop new tools and compare the three-dimensional arrangement of key molecular elements of potential drugs and the receptor sites with which they interact (11/7) |
Unigene Laboratories Inc. (OTC BB: UGNE) | Pfizer Inc. | Additional collaboration to existing partnership focused on the oral calcitonin program | ND | The additional collaboration will investigate the feasibility of orally delivering peptides for the treatment of specific endocrine disorders (10/26) |
Union Biometrica Inc.* | Aventis SA (France) | Research and development collaboration for instrumentation and tools | ND | Companies will use the instrumentation and tools for the rapid screening of the nematode Caenorhabditis elegans (12/11) |
ViroLogic Inc. (VLGC) | Bristol-Myers Squibb Co. | Agreement to jointly educate physicians about HIV resistance testing and conduct new research | ND | The companies will sponsor a series of continuing medical education programs; they also will collaborate on HIV therapy and resistance studies employing PhenoSense HIV resistance test and including research on BMY's drugs Videx and Zerit (11/2) |
ViroLogic Inc. (VLGC) | F. Hoffmann-La Roche Ltd. (Switzerland) | Research agreement to provide drug resistance testing services | ND | ViroLogic will provide the services in the Phase III clinical program involving the HIV drug, T-20, being co-developed by Roche and Trimeris Inc. (TRMS); ViroLogic will use PhenoSense to determine HIV resistance to approved antiretroviral drugs (10/31) |
VistaGen Inc.* | Pfizer Inc. | Collaboration to VistaGen's mouse-derived stem cell-based Genesis Screen technology | ND | Companies will collaborate in a joint development program and evaluation of the utility of the technology as a tool for clinically predictive toxicology screening assays (10/23) |
Vysis Inc. (VYSI) | F. Hoffmann-La Roche Ltd. (Switzerland) | Path Vysion HER-2 breast cancer test kit | ND | Collaboration will allow for the use of the kit outside the U.S. (12/6) |
Zonagen Inc. (ZONA) | Wyeth-Ayerst Laboratories (unit of American Home Products Corp.) | Option agreement to collaborate in the development of a human immunocontraceptive vaccine | $22.5 | Wyeth-Ayerst has the right to exercise its option for worldwide rights to the zona pelludida contraceptive technology through the payment of an up-front fee and entering into an exclusive license agreement, in which Wyeth-Ayerst will pay for clinical development and marketing and could pay milestones totaling $22.5M, plus royalties (12/13) |
NOTES |
||||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. |
||||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market. |
||||
** Denotes the date the item ran in BioWorld International. |
||||
|
ND = Not disclosed, reported and/or available |
||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange |
||||